CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech

  • CureVac N.V. CVAC has moved to assert its intellectual property rights, accumulated over two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development. 
  • CureVac has filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech SE BNTX and two of its subsidiaries, seeking fair compensation for infringement of a portfolio of CureVac’s intellectual property rights utilized in Comirnaty, BioNTech and Pfizer Inc’s PFE mRNA COVID-19 vaccine. 
  • Related: CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial.
  • CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale, or distribution of Comirnaty by BioNTech and its partner Pfizer.
  • The CureVac intellectual property portfolio protects multiple inventions considered essential to the design and development of BioNTech’s SARS CoV-2 mRNA vaccine, among others. 
  • These relate to the engineering of mRNA molecules, including sequence modifications to increase stability and enhance protein expression and mRNA vaccine formulations specific to SARS CoV-2 vaccines.
  • Price Action: BNTX shares are down 5.17% at $149.35 during the premarket session on the last check Tuesday.

Posted In: BriefsCOVID-19 CoronavirusCOVID-19 Vaccinewhy it's movingBiotechLarge CapNewsHealth CareLegalMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.